Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective follow-up study of ustekinumab in psoriatic arthritis
NL-OMON40967Phase 4Recruiting
- Sponsor
- Jan van Breemen Institute
- Start
- Jan 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ustekinumab in psoriatic arthritis (PsA), sponsored by Jan van Breemen Institute. Primary endpoints: DAS28 score and response, PASI response and 1 more. Started Jan 2016; status: recruiting.
02
Drugs
ustekinumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NL-OMON40967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40967.